Investor interest in the cannabis industry is heating up again, thanks to reports that the Drug Enforcement Administration (DEA) is reviewing a recommendation to reschedule marijuana to a Schedule III drug. If the DEA does reschedule the drug, it would be a major fundamental win for cannabis companies in terms of taxation, labor, research, and more.
In particular, U.S. cannabis companies that are multi-state operators (MSOs) are primed to benefit substantially from increased federal clarity on marijuana. Many of these “pure play” cannabis stocks are priced under $5 per share and trade over the counter – which means they’re somewhat more speculative and risky, but there’s also substantial growth potential for investors who can stomach that risk.
Here’s a look at three-low priced pot stocks that analysts expect to rally 38% or more from current levels.
Cresco Labs Stock
Chicago-based Cresco Labs (CRLBF) operates the Sunnyside dispensary chain, as well as flower, vapes, and edibles under brand names including Cresco, High Supply, and FloraCal Farms. Valued at a market cap of $546 million, the stock is down about 17% over the past 52 weeks.
Last quarter, Cresco reported adjusted EBITDA of $49 million, with revenue arriving at a stronger-than-forecast $191 million. EPS of $0.05 also beat analysts’ expectations. Operating cash flow jumped to $41 million.
Analysts’ recommendations for Cresco Labs are positive, with the consensus calling it a “strong buy.” Based on 9 analysts offering recommendations, 6 suggest a “strong buy,” 1 suggests a “moderate buy,” and 2 suggest a “hold.” Plus, the average price target is $3.55, implying expected upside of 120.5%.
Curaleaf Holdings Stock
Curaleaf Holdings (CURLF) is a major cultivator and distributor of cannabis via over 150 dispensaries in 19 states. With a market cap of $2.67 billion, the shares still trade below $5 each.
Over the last 52 weeks, CURLF has gained 6.3%.
CURLF missed on its latest earnings, with the loss per share of $0.09 and revenue of $333.17 million both falling short of expectations. In fiscal year 2024, Wall Street expects the company’s bottom-line deficit to narrow substantially to $0.14 per share.
Analysts expect more upside for Curaleaf stock in the year ahead, with the average 12-month price target of $5.86 representing a premium of 38.5%. Based on 10 analysts offering recommendations, 7 suggest a “strong buy,” 1 suggests a “moderate buy,” and 2 suggest a “hold.”
Verano Holdings Stock
Verano Holdings (VRNOF) is another cannabis stock under $5 that’s worth considering. Valued at $1.58 billion by market cap, the company operates across 13 states through dispensary locations, and also offers cannabis products under various brand names.
VRNOF stock has rallied more than 60% over the past 52 weeks, but analysts see even more upside ahead for this MSO.
Last quarter, VRNOF matched Wall Street’s expectations with a loss of $0.03 per share, though revenue of $240.09 million was lighter than anticipated. Looking ahead, analysts are targeting revenue growth of 5.7% for fiscal year 2024, with losses expected to narrow to $0.08 per share for the full year.
Overall, analysts are unanimously bullish on VRNOF, with 6 recommending a “strong buy” and 2 recommending a “moderate buy.” The mean price target of $7.84 implies expected upside of about 65% from current levels.
On the date of publication, Ebube Jones did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.